Technical Analysis for CNTB - Connect Biopharma Holdings Limited

Grade Last Price % Change Price Change
B 21.98 -11.66% -2.90
CNTB closed down 11.66 percent on Tuesday, July 27, 2021, on 5.58 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Down
Historical CNTB trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion -11.66%
Overbought Stochastic Strength -11.66%
New 52 Week Closing High Bullish -15.46%
New 52 Week High Strength -15.46%
Older End-of-Day Signals for CNTB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 10 DMA about 13 hours ago
Rose Above Previous Day's High about 14 hours ago
Outside Day about 14 hours ago
Up 3% about 14 hours ago
Reversed from Down about 14 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Connect Biopharma Holdings Limited Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Animal Physiology Chronic Rhinosinusitis Skin Inflammation Human Physiology Nasal Polyps

Is CNTB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 27.14
52 Week Low 14.02
Average Volume 68,719
200-Day Moving Average 0.00
50-Day Moving Average 18.98
20-Day Moving Average 22.48
10-Day Moving Average 24.11
Average True Range 1.90
ADX 49.54
+DI 24.69
-DI 15.33
Chandelier Exit (Long, 3 ATRs) 21.44
Chandelier Exit (Short, 3 ATRs) 24.21
Upper Bollinger Bands 26.54
Lower Bollinger Band 18.42
Percent B (%b) 0.44
BandWidth 36.13
MACD Line 1.58
MACD Signal Line 1.66
MACD Histogram -0.0791
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.84
Resistance 3 (R3) 28.49 27.19 26.86
Resistance 2 (R2) 27.19 25.70 26.86 26.54
Resistance 1 (R1) 24.58 24.77 23.93 23.93 26.21
Pivot Point 23.28 23.28 22.96 22.96 23.28
Support 1 (S1) 20.68 21.79 20.03 20.03 17.75
Support 2 (S2) 19.38 20.87 19.05 17.42
Support 3 (S3) 16.77 19.38 17.10
Support 4 (S4) 16.12